A new report by visiongain, a London-based business information provider, forecasts that the worldwide vaccines market will reach $20.8bn in 2015.
That market generated $10.7bn in 2010, according to VaccineManufacturing Technology and Services: World Market 2011-2021, published inOctober 2011.
Markets and R&D pipelines for vaccines remain strong, with opportunities for vaccine manufacturing specialists. Pharmaceutical companies and contract manufacturing organisations (CMOs) will benefit. In 2011, leading manufacturers of vaccines include Sanofi, Merck & Co. and GSK. This new study forecasts potential revenues for vaccines at total world and submarket levels to 2021. It also shows revenue predictions for contract vaccine manufacturing. There are forecasts of vaccine volumes (by dose), including geographical production data. Dr Sharmarke Mohamed, healthcare industry analyst, says: "Vaccines are responsible for some of the greatest public health triumphs. Those achievements include the eradication of naturally-occurring smallpox. Historically, the vaccines market had a wide range of companies vying for market share. However, small-molecule therapies took centre stage at the expense of vaccines. Looking ahead, we expect greater competition in the vaccines market, with more companies making significant headway. Leading companies will react by diversifying their portfolios with new therapeutic vaccines and outsourcing more vaccine manufacturing. Also, universities and other research institutions will play a significant role in the discovery of therapeutic vaccines."
Visiongain predicts that the vaccines industry and market will grow steadily to 2021. The future of vaccine manufacturing is promising, with potential benefits for pharma companies, contract manufacturers, patients and healthcare providers. This new report adds to visiongain's wide range of analytical reports for healthcare and other industries.
No comments:
Post a Comment